Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Biotechnology

Healthcare
$2.95 -0.94%

-$0.05 today

Market cap
$244.23M
Beta
1.39
P/E (TTM)
-4.6
EPS (TTM)
-$1.08
52W Low $3.60High $10.99

Volume 1.76M

Average 0.86M

LXEO Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables outflow grows to $0

Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How LXEO compares with its peers on the latest reported figures

  • LXEO's LTM Mar 2026 accounts receivables of $0 is the 7th largest of the 11 companies compared; the peer median is $0.
LXEO Competitors Peer median
Accounts Receivables for LXEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$12.33M +56.3%+89.9%5.7%
SLNSilence Therapeutics plcLTM Mar 2026$8.33M ——904.4%
AMRNAmarin Corporation plcLTM Mar 2026$1.05M -111.1%—0.5%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$465K -65.5%-17.4%1.3%
MREOMereo BioPharma Group plcLTM Mar 2026$345.69K +257.1%—69.1%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$59.83K -100.0%——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$0 ———
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 ———
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$0 ———
DBVTDBV Technologies S.A.LTM Mar 2026$0 ———
Peer median (excluding LXEO) $0-65.5%+36.3%5.7%

Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.62M)(59.28M)(66.39M)(98.33M)(99.96M)
Depreciation & Amortization13K1.15M1.84M2M379K
Deferred Income Tax00000
Stock-Based Compensation386K1.78M3.04M12.47M12.13M
Change in Working Capital6.04M1.79M1.48M2.73M(9.52M)
Accounts Receivables00000
Inventory00000
Accounts Payables3.02M(426K)(180K)2.38M(1.56M)
Other Working Capital3.03M2.22M1.66M351K(7.95M)
Other Non-Cash Items00530K(23K)(1.6M)
Operating Cash Flow(44.18M)(54.56M)(59.5M)(81.15M)(98.56M)
Capital Expenditures(188K)(901K)(165K)(481K)(397K)
Acquisitions (Net)00000
Purchases of Investments000(93.6M)(195.4M)
Sales of Investments0000105.53M
Other Investing Activities0(229K)(50K)017K
Investing Cash Flow(188K)(901K)(165K)(94.08M)(90.25M)
Debt Repayment0(163K)3.58M(410K)(533K)
Common Stock Issued170K332K100.25M88.71M217.33M
Common Stock Repurchased000(17K)0
Dividends Paid00000
Other Financing Activities(203K)332K(35K)491K0
Financing Cash Flow150.86M189K103.79M88.78M216.8M
Effect of Forex Changes00000
Net Change in Cash106.49M(55.27M)44.13M(86.45M)27.98M
Free Cash Flow(44.37M)(55.46M)(59.66M)(81.63M)(98.96M)

Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Intrinsic Alpha fair value

Locked

Current Price

$2.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.